March 08, 2026 — 47 articles reviewed
This cycle was dominated by a single Israeli research study on CBD and CBG for fatty liver disease that received extraordinary media coverage across multiple outlets, alongside important advances in cannabinoid drug delivery science. Regulatory and policy developments from several U.S. states and Canadian provinces rounded out a news feed with clear clinical implications for metabolic disease management, formulation science, and patient access.
🫁 CBD and CBG for Fatty Liver Disease: One Study, Very Wide Coverage
A preclinical study led by Prof. Joseph Tam’s team in Israel demonstrated that cannabidiol (CBD) and cannabigerol (CBG) reduce hepatic lipid accumulation and improve metabolic markers in models of metabolic-associated fatty liver disease, and this single study generated well over a dozen articles across outlets this cycle. The findings are mechanistically meaningful because NAFLD affects roughly 25 percent of the global population and currently has no FDA-approved pharmacological treatment beyond lifestyle modification. CB2 receptor activation appears to confer anti-inflammatory and antifibrotic hepatic benefits, while the non-intoxicating profile of CBD and CBG makes them attractive candidates for further development. Clinicians should recognize this as promising preclinical work that does not yet support therapeutic recommendations, but it does warrant tracking and informed patient counseling when families ask about cannabis and liver health. The practical takeaway is to screen patients with metabolic syndrome for cannabis use, document it, and watch for human clinical trials that could change the treatment landscape within the next several years.
- #78Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease
- #78Study reveals cannabis compounds reduce threat of fatty liver disease | Health
- #75Cannabis Compounds CBD and CBG Show Promise in Reducing Liver Fat and Improving …
- #75Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic Health
- #75Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
- #75Study reveals cannabis compounds reduce threat of fatty liver disease | Health – News-Topic
- #72Study reveals cannabis compounds reduce threat of fatty liver disease | Health – WFMZ.com
💊 Oral Mucosal Delivery: Solving the Bioavailability Problem
A comprehensive review published in PubMed on oral mucosal cannabinoid delivery systems received repeated coverage this cycle, highlighting formulation strategies designed to bypass hepatic first-pass metabolism and improve dosing consistency. Poor water solubility, variable absorption, and unpredictable pharmacokinetics remain the central barriers preventing cannabinoid therapies from achieving the reliability clinicians expect from conventional pharmaceuticals. Sublingual, buccal, and mucoadhesive formulations using lipid-based systems and nanoparticulate carriers show potential to deliver faster onset, more predictable blood levels, and reduced inter-patient variability. For clinicians currently navigating the trial-and-error dosing reality of cannabis medicine, these formulation advances represent a genuine path toward standardized, reproducible therapeutic outcomes. Until these products reach market, providers should counsel patients that current product variability is a known limitation and that careful titration remains essential.
- #78Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed
⚖️ State Policy Updates: Access Expanding, Oversight Lagging
Legislative and regulatory activity spanned multiple states this cycle, with Alabama preparing for its spring 2026 dispensary launch, Tennessee debating legalization tied to infrastructure revenue, West Virginia allocating $20 million to university cannabis research, Utah refining its medical program, and Georgia considering protections for medical cannabis patients against odor-based police searches. West Virginia’s research funding commitment stands out as a model for building the institutional evidence base that cannabis medicine urgently needs. Georgia’s House Bill 496 addresses a real clinical barrier: patients avoiding treatment or failing to disclose cannabis use because they fear arrest despite holding valid prescriptions. Clinicians in all of these states should begin preparing now by developing counseling protocols, documentation systems, and familiarity with their state’s qualifying conditions and product standards. The overall trend is clear: access is expanding faster than clinical infrastructure, which places the burden of responsible guidance squarely on providers.
- #72House Bill 496 in Georgia would stop police from stopping, searching, or arresting … – Instagram
- #60Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown
- #55West Virginia House Passes Bill To Allocate Medical Marijuana Revenue, With Some …
- #45Alabama Medical Cannabis Sales Gear for Spring 2026 Launch
- #452026 Utah legislature on cannabis, psychedelics and kratom – Fox 13
- #45The legislation aims to legalize marijuana in Tennessee and use the revenue to repair … – Facebook
🚗 Roadside THC Testing: Presence Is Not Impairment
A single investigative report on roadside THC testing and Saskatchewan’s zero-tolerance driving policy received multiple pickups this cycle, highlighting a persistent problem in cannabis medicine: current detection technology measures cannabinoid presence, not functional impairment. THC can remain detectable in saliva for days or weeks after use, particularly in regular therapeutic users, meaning a positive roadside test carries no reliable correlation to driving ability at the time of testing. Oregon’s “green lab” training program for officers represents an attempt to standardize impairment recognition, but even improved officer training cannot overcome the fundamental scientific limitation of presence-based testing. Clinicians prescribing cannabis should document medical necessity clearly, counsel patients against driving while subjectively impaired, and inform them that positive roadside screens may carry legal and insurance consequences regardless of actual impairment status. This remains one of the most significant unresolved medicolegal issues in cannabis medicine today.
- #65Green lab’ helps Oregon officers recognize marijuana-impaired driving | The Astorian
- #45The science behind roadside THC testing and diving into SGI’s zero-tolerance policy – Global News
🧩 Product Safety, Pediatric Risk, and the GLP-1 Connection
A Georgia mother’s cannabis oil formulation for her daughter’s severe autism entered the dispensary market, Ohio recalled mislabeled THC gummies, Oregon failed to pass a 10mg edible potency cap, and a large study suggested GLP-1 receptor agonists may reduce addiction risk across multiple substances including cannabis. The Georgia story illustrates both the innovation driven by desperate families and the urgent need for standardized pediatric cannabis research so that clinicians can move beyond anecdotal reports. Ohio’s labeling recall and Oregon’s failed potency legislation underscore that product safety infrastructure has not kept pace with market growth, particularly regarding pediatric accidental exposure. The GLP-1 findings open a genuinely novel pharmacological avenue for cannabis use disorder by targeting shared reward pathway dysregulation rather than treating addiction as an isolated behavioral problem. Clinicians should ask about cannabis use in pediatric populations, counsel on secure storage in all households, and monitor the GLP-1 addiction literature as it evolves toward clinical application.
- #62Weight loss drugs may reduce risk of addiction, study finds – Dagens.com
- #55Oregon Bill To Ban Marijuana Edibles With More Than 10 Milligrams Of THC Fails
- #45Mom’s homemade medical cannabis recipe now being sold at Ga. dispensaries – WRDW
- #45Ohio Department of Commerce recalls certain marijuana gummies lacking THC symbol … – Facebook
- #35Popular Diabetes Drugs May Help Combat Multiple Addictions, Major Study Shows
The liver disease findings are the most clinically consequential signal in this cycle, not because they change practice today, but because they give us a mechanistic foundation that has been missing from the cannabis-and-metabolic-health conversation for years. The rest of this feed tells the same story it always does: the science is advancing, the formulations are improving, and the policy is scrambling to keep up.
Digest-Level Clinical Commentary
# Clinical Reflection The amplified media coverage of the Israeli CBD and CBG fatty liver disease study suggests we’re entering a phase where isolated positive findings receive disproportionate public attention, which will likely increase patient inquiries about cannabinoids for metabolic conditions before robust replication data exists. This pattern, combined with the concurrent regulatory fragmentation across U.S. states and Canadian provinces, underscores my clinical challenge to distinguish between genuine therapeutic signals and media-driven expectations while navigating an increasingly inconsistent legal landscape. As practitioners, we need stronger guidance on counseling patients about non-alcoholic fatty liver disease specifically, since the mechanistic plausibility is there but the human efficacy and optimal dosing remain undetermined.
# Clinical Perspective The concentrated media attention on a single Israeli study examining CBD and CBG for fatty liver disease reflects the broader pattern of cannabis research generating disproportionate public interest relative to the strength and replicability of the underlying evidence. While regulatory expansion across North American jurisdictions continues to outpace robust clinical guidance, clinicians should remain cautious about interpreting preliminary cannabinoid research as actionable for patient management until findings are validated in larger, controlled trials and mechanisms of action are better understood. The gap between public enthusiasm and clinical evidence underscores the need for measured communication about cannabis-derived compounds in healthcare settings.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: